SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiRegenerative MedicineCell TherapyGene Therapy

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161951

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161951

Exosome-based Cancer Therapy CDMO Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 275 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

The Exosome-based Cancer Therapy CDMO Market serves developers of oncology therapies built on extracellular vesicles, which can carry drugs, nucleic acids or immune signals to target cells. Many of these developers are early-stage biotechnology companies that lack in-house manufacturing, so they rely on contract development and manufacturing organisations for process development, analytics and GMP production. In 2026, the market is valued at US$200 Mn and is projected to reach US$600 Mn by 2033, registering a CAGR of 17.00%. This rapid growth begins from a small base, reflecting a field that is still largely in preclinical and early clinical stages.

The market includes process development, analytical development and characterisation, clinical-scale GMP manufacturing, fill-finish and packaging, and regulatory and quality support. Exosomes are sourced from mesenchymal stem cells, immune cells, tumour cells and engineered cell lines, and isolated using techniques ranging from ultracentrifugation to tangential flow filtration and chromatography. Low vesicle yields and the absence of agreed potency assays remain major challenges, making technical expertise a key differentiator for service providers.

Market Insights

By service type, the market includes process development, analytical development and characterization, clinical-scale GMP manufacturing, fill-finish and packaging, and regulatory and quality support. Exosome sources comprise mesenchymal stem cell-derived, immune cell-derived, tumor cell-derived and engineered cell line-derived vesicles. Isolation technologies include ultracentrifugation, tangential flow filtration, size-exclusion chromatography, ion-exchange and affinity chromatography, and precipitation and kit-based methods. End users are biotechnology companies, pharmaceutical companies, academic and research institutes, and government and nonprofit research programs.

A key trend is the shift from ultracentrifugation to closed tangential flow filtration, which is growing at a CAGR of 22.1% as manufacturers adapt to EU GMP requirements for sterile production. Clinical-scale GMP manufacturing is expanding at 21.4%, reflecting the movement of programmes into human trials. Pharmaceutical company clients are growing at 19.6%, showing increasing interest from larger drug developers. Engineered cell-line sources are gaining share, as developers seek more consistent and scalable starting material for therapeutic vesicles.

Drivers

The expansion of early-phase oncology vesicle pipelines is the leading driver, with high impact over the medium term. Many developers are advancing exosome therapies without in-house manufacturing capacity, so they outsource process development and production to GMP suites operated by specialised providers. As more candidates move toward clinical trials, demand for these outsourced services grows steadily.

Regulatory pressure is a second driver, with medium impact in the short term. Authorities expect clinical material to come from documented GMP suppliers, which encourages developers to work with established contract manufacturers rather than producing material in research laboratories. The market also faces restraints. Low vesicle yields and unresolved scale-up economics per batch present a high, long-term challenge, raising the cost of producing enough material for trials and future commercial supply. In addition, the lack of agreed potency assays and characterisation standards, a medium-term restraint, complicates quality control and regulatory submissions, making it harder for developers and service providers to demonstrate consistent product performance.

Business Opportunity

Cargo loading and vesicle engineering services form a premium fee pool beyond isolation. Many exosome therapies depend on loading drugs, RNA or other molecules into vesicles or modifying their surfaces to target specific cells. These steps are technically complex, and developers often lack the expertise to perform them reliably at scale. Contract providers that offer validated loading and engineering capabilities can charge higher fees and become strategic partners rather than simple manufacturing suppliers.

Small-batch, catalogue-priced clinical supply offers another opportunity. Investigator-initiated oncology trials, often led by academic and hospital researchers, need modest quantities of GMP-grade material but may lack the budgets for fully customised development programmes. Providers that offer standardised, catalogue-priced batches can serve this segment efficiently and build relationships with researchers whose programmes may later grow. Combined with the move to tangential flow filtration and rising demand from pharmaceutical clients, these opportunities reward providers that combine scientific expertise, flexible capacity and transparent pricing.

Region Analysis

North America is the leading region in the Exosome-based Cancer Therapy CDMO Market, holding a 46% share. The region's concentration of oncology-focused biotechnology companies, strong venture funding and established contract manufacturing infrastructure support its leadership. Europe follows with a 27% share, where research strength in extracellular vesicles and clear GMP expectations for sterile production encourage outsourcing to qualified providers.

Asia Pacific accounts for a 19% share and is the fastest-growing region, expanding at a CAGR of 21.3%. Growing biotechnology investment, expanding clinical research activity and increasing contract manufacturing capacity are supporting regional growth. Latin America represents a 4% share, with activity mainly linked to academic research and early collaborations. The Middle East and Africa hold a 4% share, where research programmes and new biotechnology initiatives are creating early demand. Across all regions, progress in yield improvement, potency testing and standardised characterisation will strongly influence how quickly exosome cancer therapies advance and how much demand reaches contract providers.

Key Players

  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.
  • RoosterBio, Inc.
  • Creative Biolabs
  • Exopharm Limited
  • System Biosciences, LLC
  • Evox Therapeutics Limited
  • ILIAS Biologics Inc.
  • WuXi AppTec Co., Ltd.

Segmentation

By Service Type:

  • Process Development
  • Analytical Development and Characterization
  • Clinical-Scale GMP Manufacturing
  • Fill-Finish and Packaging
  • Regulatory and Quality Support

By Exosome Source:

  • Mesenchymal Stem Cell-Derived
  • Immune Cell-Derived
  • Tumor Cell-Derived
  • Engineered Cell Line-Derived

By Isolation Technology:

  • Ultracentrifugation
  • Tangential Flow Filtration
  • Size-Exclusion Chromatography
  • Ion-Exchange and Affinity Chromatography
  • Precipitation and Kit-Based Methods

By End User:

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic and Research Institutes
  • Government and Nonprofit Research Programs

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Exosome-based Cancer Therapy CDMO Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 3.1. Global Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 3.1.1. Process Development
    • 3.1.2. Analytical Development and Characterization
    • 3.1.3. Clinical-Scale GMP Manufacturing
    • 3.1.4. Fill-Finish and Packaging
    • 3.1.5. Regulatory and Quality Support
  • 3.2. Global Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 3.2.1. Mesenchymal Stem Cell-Derived
    • 3.2.2. Immune Cell-Derived
    • 3.2.3. Tumor Cell-Derived
    • 3.2.4. Engineered Cell Line-Derived
  • 3.3. Global Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 3.3.1. Ultracentrifugation
    • 3.3.2. Tangential Flow Filtration
    • 3.3.3. Size-Exclusion Chromatography
    • 3.3.4. Ion-Exchange and Affinity Chromatography
    • 3.3.5. Precipitation and Kit-Based Methods
  • 3.4. Global Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 3.4.1. Biotechnology Companies
    • 3.4.2. Pharmaceutical Companies
    • 3.4.3. Academic and Research Institutes
    • 3.4.4. Government and Nonprofit Research Programs
  • 3.5. Global Exosome-based Cancer Therapy CDMO Market Outlook, by Region, Value (US$ Mn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 4.1. North America Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 4.1.1. Process Development
    • 4.1.2. Analytical Development and Characterization
    • 4.1.3. Clinical-Scale GMP Manufacturing
    • 4.1.4. Fill-Finish and Packaging
    • 4.1.5. Regulatory and Quality Support
  • 4.2. North America Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 4.2.1. Mesenchymal Stem Cell-Derived
    • 4.2.2. Immune Cell-Derived
    • 4.2.3. Tumor Cell-Derived
    • 4.2.4. Engineered Cell Line-Derived
  • 4.3. North America Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 4.3.1. Ultracentrifugation
    • 4.3.2. Tangential Flow Filtration
    • 4.3.3. Size-Exclusion Chromatography
    • 4.3.4. Ion-Exchange and Affinity Chromatography
    • 4.3.5. Precipitation and Kit-Based Methods
  • 4.4. North America Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 4.4.1. Biotechnology Companies
    • 4.4.2. Pharmaceutical Companies
    • 4.4.3. Academic and Research Institutes
    • 4.4.4. Government and Nonprofit Research Programs
  • 4.5. North America Exosome-based Cancer Therapy CDMO Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 4.5.1. U.S. Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 4.5.2. U.S. Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 4.5.3. U.S. Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 4.5.4. U.S. Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 4.5.6. Canada Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 4.5.7. Canada Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 4.5.8. Canada Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 5.1. Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 5.1.1. Process Development
    • 5.1.2. Analytical Development and Characterization
    • 5.1.3. Clinical-Scale GMP Manufacturing
    • 5.1.4. Fill-Finish and Packaging
    • 5.1.5. Regulatory and Quality Support
  • 5.2. Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 5.2.1. Mesenchymal Stem Cell-Derived
    • 5.2.2. Immune Cell-Derived
    • 5.2.3. Tumor Cell-Derived
    • 5.2.4. Engineered Cell Line-Derived
  • 5.3. Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 5.3.1. Ultracentrifugation
    • 5.3.2. Tangential Flow Filtration
    • 5.3.3. Size-Exclusion Chromatography
    • 5.3.4. Ion-Exchange and Affinity Chromatography
    • 5.3.5. Precipitation and Kit-Based Methods
  • 5.4. Europe Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 5.4.1. Biotechnology Companies
    • 5.4.2. Pharmaceutical Companies
    • 5.4.3. Academic and Research Institutes
    • 5.4.4. Government and Nonprofit Research Programs
  • 5.5. Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 5.5.1. Germany Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.2. Germany Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.3. Germany Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.4. Germany Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.6. Italy Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.7. Italy Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.8. Italy Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.9. France Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.10. France Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.11. France Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.12. France Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.14. U.K. Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.15. U.K. Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.16. U.K. Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.18. Spain Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.19. Spain Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.20. Spain Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.22. Russia Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.23. Russia Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.24. Russia Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 5.5.26. Rest of Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 5.5.27. Rest of Europe Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 5.5.28. Rest of Europe Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 6.1. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 6.1.1. Process Development
    • 6.1.2. Analytical Development and Characterization
    • 6.1.3. Clinical-Scale GMP Manufacturing
    • 6.1.4. Fill-Finish and Packaging
    • 6.1.5. Regulatory and Quality Support
  • 6.2. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 6.2.1. Mesenchymal Stem Cell-Derived
    • 6.2.2. Immune Cell-Derived
    • 6.2.3. Tumor Cell-Derived
    • 6.2.4. Engineered Cell Line-Derived
  • 6.3. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 6.3.1. Ultracentrifugation
    • 6.3.2. Tangential Flow Filtration
    • 6.3.3. Size-Exclusion Chromatography
    • 6.3.4. Ion-Exchange and Affinity Chromatography
    • 6.3.5. Precipitation and Kit-Based Methods
  • 6.4. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 6.4.1. Biotechnology Companies
    • 6.4.2. Pharmaceutical Companies
    • 6.4.3. Academic and Research Institutes
    • 6.4.4. Government and Nonprofit Research Programs
  • 6.5. Asia Pacific Exosome-based Cancer Therapy CDMO Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 6.5.1. China Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.2. China Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.3. China Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.4. China Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.6. Japan Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.7. Japan Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.8. Japan Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.10. South Korea Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.11. South Korea Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.12. South Korea Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 6.5.13. India Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.14. India Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.15. India Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.16. India Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.18. Southeast Asia Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.19. Southeast Asia Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.20. Southeast Asia Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 6.5.22. Rest of SAO Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 6.5.23. Rest of SAO Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 6.5.24. Rest of SAO Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 7.1. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 7.1.1. Process Development
    • 7.1.2. Analytical Development and Characterization
    • 7.1.3. Clinical-Scale GMP Manufacturing
    • 7.1.4. Fill-Finish and Packaging
    • 7.1.5. Regulatory and Quality Support
  • 7.2. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 7.2.1. Mesenchymal Stem Cell-Derived
    • 7.2.2. Immune Cell-Derived
    • 7.2.3. Tumor Cell-Derived
    • 7.2.4. Engineered Cell Line-Derived
  • 7.3. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 7.3.1. Ultracentrifugation
    • 7.3.2. Tangential Flow Filtration
    • 7.3.3. Size-Exclusion Chromatography
    • 7.3.4. Ion-Exchange and Affinity Chromatography
    • 7.3.5. Precipitation and Kit-Based Methods
  • 7.4. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 7.4.1. Biotechnology Companies
    • 7.4.2. Pharmaceutical Companies
    • 7.4.3. Academic and Research Institutes
    • 7.4.4. Government and Nonprofit Research Programs
  • 7.5. Latin America Exosome-based Cancer Therapy CDMO Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 7.5.1. Brazil Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 7.5.2. Brazil Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 7.5.3. Brazil Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 7.5.4. Brazil Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 7.5.6. Mexico Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 7.5.7. Mexico Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 7.5.8. Mexico Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 7.5.10. Argentina Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 7.5.11. Argentina Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 7.5.12. Argentina Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 7.5.14. Rest of LATAM Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 7.5.15. Rest of LATAM Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 7.5.16. Rest of LATAM Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, Value (US$ Mn), 2020-2033
    • 8.1.1. Process Development
    • 8.1.2. Analytical Development and Characterization
    • 8.1.3. Clinical-Scale GMP Manufacturing
    • 8.1.4. Fill-Finish and Packaging
    • 8.1.5. Regulatory and Quality Support
  • 8.2. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, Value (US$ Mn), 2020-2033
    • 8.2.1. Mesenchymal Stem Cell-Derived
    • 8.2.2. Immune Cell-Derived
    • 8.2.3. Tumor Cell-Derived
    • 8.2.4. Engineered Cell Line-Derived
  • 8.3. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, Value (US$ Mn), 2020-2033
    • 8.3.1. Ultracentrifugation
    • 8.3.2. Tangential Flow Filtration
    • 8.3.3. Size-Exclusion Chromatography
    • 8.3.4. Ion-Exchange and Affinity Chromatography
    • 8.3.5. Precipitation and Kit-Based Methods
  • 8.4. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 8.4.1. Biotechnology Companies
    • 8.4.2. Pharmaceutical Companies
    • 8.4.3. Academic and Research Institutes
    • 8.4.4. Government and Nonprofit Research Programs
  • 8.5. Middle East & Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 8.5.1. GCC Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 8.5.2. GCC Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 8.5.3. GCC Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 8.5.4. GCC Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 8.5.6. South Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 8.5.7. South Africa Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 8.5.8. South Africa Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 8.5.10. Egypt Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 8.5.11. Egypt Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 8.5.12. Egypt Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 8.5.14. Nigeria Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 8.5.15. Nigeria Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 8.5.16. Nigeria Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East Exosome-based Cancer Therapy CDMO Market Outlook, by Service Type, 2020-2033
    • 8.5.18. Rest of Middle East Exosome-based Cancer Therapy CDMO Market Outlook, by Exosome Source, 2020-2033
    • 8.5.19. Rest of Middle East Exosome-based Cancer Therapy CDMO Market Outlook, by Isolation Technology, 2020-2033
    • 8.5.20. Rest of Middle East Exosome-based Cancer Therapy CDMO Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Lonza Group AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Charles River Laboratories International, Inc.
    • 9.4.3. Catalent, Inc.
    • 9.4.4. RoosterBio, Inc.
    • 9.4.5. Creative Biolabs
    • 9.4.6. Exopharm Limited
    • 9.4.7. System Biosciences, LLC
    • 9.4.8. Evox Therapeutics Limited
    • 9.4.9. ILIAS Biologics Inc.
    • 9.4.10. WuXi AppTec Co., Ltd.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!